title: Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.
abstract: A significant reduction in plasma high density lipoprotein (HDL) cholesterol is a recognised consequence of treatment with probucol. By contrast, fibrate therapy in general has the opposite effect. We report two cases where the combination of probucol and a fibrate led to profoundly reduced plasma levels of HDL cholesterol associated with very low levels of apolipoprotein A-I (apoA-I). In the first, bezafibrate was added to probucol, and in the second, probucol added to a combination of simvastatin and fenofibrate. In both cases, plasma levels of HDL and apoA-I returned towards normal after discontinuation of one or both drugs, indicating that the reduction was reversible.
authors.affiliation: Institute of Biochemistry, Royal Infirmary, Glasgow, UK.
authors.forename: M J
authors.initials: MJ
authors.lastname: Murphy
authors.forename: A
authors.initials: A
authors.lastname: Duncan
authors.forename: B D
authors.initials: BD
authors.lastname: Vallance
authors.forename: C J
authors.initials: CJ
authors.lastname: Packard
authors.forename: D S
authors.initials: DS
authors.lastname: O'Reilly
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000009:adverse effects*; D001629:Bezafibrate / Q000009:adverse effects*; D008076:Cholesterol, HDL / Q000097:blood*; D004347:Drug Interactions; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects*; D006801:Humans; D007009:Hypolipoproteinemias / Q000139:chemically induced*; D008148:Lovastatin / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D011341:Probucol / Q000009:adverse effects*; D019821:Simvastatin
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008148:Lovastatin; D019821:Simvastatin; D011341:Probucol; D011345:Fenofibrate; D001629:Bezafibrate